Inscripta  

Boulder,  CO 
United States
https://www.inscripta.com/
  • Booth: 1427

Inscripta has developed the world’s first benchtop platform for scalable Digital Genome Engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, reagents, and software, offers a fully automated workflow that enables multiplexed, trackable editing of cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research purposes, the company is enabling scientists to realize a new era of biological discovery. Inscripta is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego.

Brands: Onyx


 Press Releases

  • Results from a 200,000-edit library of an E. coli biosynthesis pathway show unprecedented scale and variety of edit types

    Boulder, CO – June 17, 2019 – Inscripta, developer of the first scalable benchtop Digital Genome EngineeringTM platform, today announced the company will be making its first public presentation about its CRISPR-based technology at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference. The meeting takes place June 23-27 in New York City.

    Richard Fox, Ph.D., Executive Director of Data Science at Inscripta and inventor of the protein sequence activity relationship (ProSAR) algorithm, will present results from a 200,000-edit library consisting of a large variety of edit types to an E. coli biosynthesis pathway that revealed novel biology. His talk will take place on June 25, 2019 from 12:45-1:30 p.m.

    “Existing methods for CRISPR-based gene editing are limited by throughput, access, and cost. There is a critical need for scalable alternatives that would allow researchers to rapidly create a wide variety of edit types in novel combinations,” said Dr. Fox. “I am thrilled to share with the synthetic biology community the first data from our platform, which will unlock the power to create edits at genome scale. This will accelerate researchers’ ability to perform forward genome engineering to address some of society’s most pressing problems.”

    Kevin Ness, Ph.D., Chief Executive Officer of Inscripta, commented: “We are at the dawn of being able to engineer biological systems at previously unattainable scale and complexity. Soon researchers will be limited only by their imaginations and capacity to explore the many ways this technology will transform major economic sectors such as healthcare, agriculture, energy, and materials. We are excited to start sharing what we have been working on with the world and to introduce our commercial platform later this year.”

    About Inscripta

    Inscripta is developing the world’s first scalable platform for benchtop Digital Genome Engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, reagents, and software, will offer a fully automated workflow that enables multiplexed, trackable editing of cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research purposes, the company is enabling scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo, with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, MLS Capital, and NanoDimension. For more information, visit www.inscripta.com.


 Products

  • Onyx Digital Genome Engineering Platform
    The fully automated Onyx Digital Genome Engineering Platform platform is a complete benchtop solution, consisting of design and analysis software, custom consumables, and a fully automated instrument for genome engineering....

  • Inscripta introduces the fully automated Onyx Digital Genome Engineering Platform. Current gene-editing techniques are insufficient to realize the full potential of genome engineering; they lack the required scale, performance, and access. With the Inscripta Onyx platform, you can build the most extensive libraries, engineered with the widest variety of edit types—all with the push of a single button. The Onyx platform is a complete benchtop solution, consisting of design and analysis software, custom consumables, and a fully automated instrument. No expert gene-editing knowledge is required. Bring genome engineering at scale to your lab, making the previously impossible a reality. Only with the Onyx Digital Genome Engineering Platform.

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.